Monthly Archives: March 2011
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals collaborate
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals have today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept’s FXR agonist obeticholic acid (OCA, also known as INT-747). DSP will advance OCA in Japan … Continue reading
Filed under alliances
Takeda/Amgen’s motesanib fails in Phase 3 trial
Takeda and Amgen have announced the top-line results from the MONET1 Phase 3 trial evaluating motesanib diphosphate administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer. According to the companies the trial … Continue reading
Filed under alliances
Graffinity Pharmaceuticals signs collaboration with Shionogi
Graffinity Pharmaceuticals has announced that it has entered into a research collaboration with Shionogi & Co. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small … Continue reading
Filed under alliances
Merck Serono expands collaboration with Newron
Merck Serono has announced that it has entered into an agreement that broadens the scope of the collaboration with Newron Pharmaceuticals. The two companies are already collaborating on the development of safinamide in Parkinson’s disease. Under the terms of the … Continue reading
Gilead Sciences signs cancer collaboration with Yale
Gilead Sciences has announced that it has formed a research collaboration with Yale School of Medicine to focus on discovery of novel cancer therapies. The research effort will initially span four years, with an option to renew for up to … Continue reading
Filed under alliances
Core Essence Orthopaedics receives $11.5 million in series B funding
Core Essence Orthopaedics, a medical device company focused on MIS arthroscopic and endoscopic procedures involving soft tissue and skeletal repair, has announced that it has closed a $11.5 million Series B financing. Participants include Baird Venture Partners, NewSpring Health Capital … Continue reading
Filed under funding
Valeant Pharmaceuticals makes bid for Cephalon
Cephalon has confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals to acquire the company for $73 a share or to purchase Cephalon’s non-oncology related assets for $2.8 billion. Cephalon is reviewing the bid and plans to respond … Continue reading
Filed under acquisitions
Trobalt approved in Europe
GlaxoSmithKline and Valeant Pharmaceuticals have announced that European regulators approved Trobalt (retigabine) as an adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy, marking the first authorisation for the product. The decision followed a … Continue reading
Filed under alliances
Champions signs collaboration agreement with Cephalon
Champions Biotechnology has announced the signing of a technology collaboration agreement with Cephalon, Inc. in which Champions will conduct low passage Tumorgraft studies on two proprietary chemical compounds, CEP-32496, an inhibitor of mutant B-Raf, and CEP-37440, a selective dual ALK-FAK … Continue reading
Filed under alliances
Pronova settles Apotex litigation
GlaxoSmithKline has announced that Pronova BioPharma Norge AS, which owns the patents for LOVAZA, has entered into an agreement with Apotex to settle their patent litigation in the US related to LOVAZA. GlaxoSmithKline has the marketing rights for LOVAZA in … Continue reading
Filed under litigation
